Highlights MetaStat, Inc.

Equities

MTST

US59140A2033

Market Closed - OTC Markets Other stock markets 18:47:00 27/07/2023 BST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-.--%

2018	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
2017	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	21/06/18	CI
MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation	19/06/17	CI
MetaStat, Inc. Presents Supportive Data for the Role of Mena Protein Isoforms in Tumor Dissemination at the 2017 American Association of Cancer Research Annual Meeting	06/04/17	CI
MetaStat, Inc. Receives Additional State Clinical Laboratory Licenses	19/12/16	CI
MetaStat, Inc. Presents Positive Data from Two Clinical Studies of Metasite Breast at 2016 San Antonio Breast Cancer Symposium	13/12/16	CI
MetaStat, Inc. and Celgene Corporation Enter into Amendment to Pilot Materials Transfer Agreement	06/10/16	CI
MetaStat Announces Completion of Analytical Validation Study of its MenaCalc Cancer Diagnostic Platform	26/01/16	CI
MetaStat, Inc. Announces Positive Analytical Validation Data for MetaSite Breast™ Cancer Diagnostic Test	02/12/15	CI
Reverse Split: 1 of 15	07/10/15	FA
Metastat, Inc. Announces Positive Topline Results of Metastat Breast Prognostic Study in Invasive Breast Cancer	23/09/15	CI
MetaStat, Inc. Announces Successful Analytical Validation of its MetaSite Breast™ Cancer Diagnostic	27/08/15	CI
MetaStat Demonstrates MenaCalc Lung™ Is Prognostic for Outcome in Non-Small Cell Lung Cancer	21/04/15	CI
MetaStat, Inc. Enters into License, Development and Commercialization Agreement with Metastat Biomedical, Inc. and Aset Therapeutics LLC	13/01/15	CI
MetaStat, Inc. Enters into License, Development and Commercialization Agreement with MetaStat BioMedical, Inc. and ASET Therapeutics LLC	02/12/14	CI
MetaStat, Inc. Completes Trial of MetaSite Breast Test to Predict Breast Cancer Metastasis	18/02/14	CI
MetaStat Enters into License Agreements for Alternative Splicing Program	31/12/13	CI
MetaStat, Inc. Announces Exclusive Worldwide License Agreements for the Alternative Splicing Program in the Epithelial to Mesenchymal Transition in Epithelial Cancers	12/12/13	CI
MetaStat, Inc. Announces Completion of 500 Patient Breast Cancer Trial	07/01/13	CI
MetaStat, Inc. acquired Photovoltaic Solar Cells, Inc. from Perkins Capital Management, Inc. and other investors in a reverse merger transaction.	28/02/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer